Compare Ishares Msci Italy ETF (EWI) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs McKesson Corporation — how do they compare? Ishares Msci Italy ETF trades at $63.25, while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation pays a 0.43% dividend while Ishares Msci Italy ETF pays none, and Ishares Msci Italy ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| EWI | MCK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $995.69 |
52-Week Low | $50.31 | $659.01 |
Market Cap | — | $102.58B |
Enterprise Value | — | $109.12B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, a US-listed stock, trades at $63.35, up 0.3% on the day, with technical indicators showing a bullish moving average trend but overbought oscillators. The stock recently hit a 52-week high, reflecting strong momentum. A dividend of $1.17 is scheduled for payment in June 2026, offering income potential. Recent news highlights European market strength and ECB policy impacts, which may influence EWI's performance given its European exposure.
The outlook for EWI is cautiously optimistic, driven by technical strength and positive European equity trends. Risks include potential ECB rate hikes and geopolitical tensions affecting energy costs. Analyst sentiment is mixed, with the stock near highs suggesting limited upside without new catalysts. Investors should weigh technical overbought signals against fundamental growth prospects.
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
